Allarity Therapeutics (FRA:C6D0) Debt-to-Equity : -0.42 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Allarity Therapeutics Debt-to-Equity?

Allarity Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €2.48 Mil. Allarity Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil. Allarity Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €-5.95 Mil. Allarity Therapeutics's debt to equity for the quarter that ended in Mar. 2024 was -0.42.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Allarity Therapeutics's Debt-to-Equity or its related term are showing as below:

FRA:C6D0' s Debt-to-Equity Range Over the Past 10 Years
Min: -11.2 Med: 0.05 Max: 1.98
Current: -0.42

During the past 5 years, the highest Debt-to-Equity Ratio of Allarity Therapeutics was 1.98. The lowest was -11.20. And the median was 0.05.

FRA:C6D0's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs FRA:C6D0: -0.42

Allarity Therapeutics Debt-to-Equity Historical Data

The historical data trend for Allarity Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allarity Therapeutics Debt-to-Equity Chart

Allarity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.05

0.11

0.06

1.98

-0.47

Allarity Therapeutics Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial											-11.19	-2.06	-0.35	-0.47	-0.42

Competitive Comparison of Allarity Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Allarity Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allarity Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allarity Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Allarity Therapeutics's Debt-to-Equity falls into.

Allarity Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Allarity Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.192	+	0)	/	-2.523
	=	-0.47

Allarity Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.475	+	0)	/	-5.953
	=	-0.42

Allarity Therapeutics (FRA:C6D0) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Allarity Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Allarity Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Allarity Therapeutics (FRA:C6D0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allarity Therapeutics Inc (FRA:C6D0) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ALLR:USA

Address

24 School Street, 2nd Floor, Boston, MA, USA

Website

https://www.allarity.com

Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improve clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.

Allarity Therapeutics (FRA:C6D0) Headlines

No Headlines